The presentation of Celularity's technology at a prestigious international congress not only validates its scientific merit but also enhances its visibility in the global medical community. This could lead to increased interest from investors and potential partners, positively impacting CELU's stock in the short term. The focus on a significant clinical opportunity like LSCD, where treatment options are limited, underscores the potential market demand for Celularity's product.